- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06779630
BIOTRONIK - en prospektiv multicenter enkeltarmsundersøgelse for at vurdere sikkerheden og effektiviteten af Orsiro Mission 48 mm SiroLimus-eluerende koronarstentsystem til behandling af forsøgspersoner med aterosklerotisk(e) læsion(er) (BIOFLOW-48)
The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) >36 mm and ≤ 44 mm in length (by visual estimate) in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm.
Patients enrolled in the United States will be followed for 2 years post index procedure with follow-up visits at 1, 6, 12 months and 2 years post index procedure. Patients enrolled outside of the United States will be followed through 5 years post index procedure with additional follow-up visits at 3 and 5 years post index procedure.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: BIOFLOW-48 Project Manager
- Telefonnummer: 1-866-246-6990
- E-mail: bioflow-48@teleflex.com
Studiesteder
-
-
California
-
Concord, California, Forenede Stater, 94520
- Rekruttering
- John Muir Medical Center
-
-
Kansas
-
Wichita, Kansas, Forenede Stater, 67214
- Rekruttering
- Ascension Via Christi Hospitals Wichita
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Rekruttering
- Henry Ford Hospital
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Barnes Jewish Hospital
-
-
New York
-
Manhasset, New York, Forenede Stater, 11030
- Rekruttering
- North Shore University Hospital
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- Columbia University Irving Medical Center/New York Presbyterian Hospital
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75226
- Rekruttering
- Baylor Scott & White The Heart Hospital - Dallas
-
Kyle, Texas, Forenede Stater, 78640
- Rekruttering
- Ascension Texas Cardiovascular
-
-
West Virginia
-
Charleston, West Virginia, Forenede Stater, 25304
- Rekruttering
- Charleston Area Medical Center
-
-
-
-
Auvergne-Rhône-Alpes
-
Lyon, Auvergne-Rhône-Alpes, Frankrig, 69002
- Aktiv, ikke rekrutterende
- Hospices Civils de Lyon - CHU de Lyon
-
-
Grand Est
-
Essey-lès-Nancy, Grand Est, Frankrig, 54270
- Aktiv, ikke rekrutterende
- Clinique Louis Pasteur
-
-
Provence-Alpes-Côte d'Azur Region
-
Saint-Laurent-du-Var, Provence-Alpes-Côte d'Azur Region, Frankrig, 06700
- Aktiv, ikke rekrutterende
- Institut Arnault Tzanck
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Frankrig, 75014
- Aktiv, ikke rekrutterende
- Hôpital Cochin - Groupe AP-HP
-
-
-
-
Lower Silesian Voivodeship
-
Lubin, Lower Silesian Voivodeship, Polen, 59-301
- Aktiv, ikke rekrutterende
- Miedziowe Centrum Zdrowia SA
-
-
-
-
Canton Ticino
-
Lugano, Canton Ticino, Schweiz, 6900
- Aktiv, ikke rekrutterende
- Istituto Cardiocentro Ticino
-
-
Canton of Basel-City
-
Basel, Canton of Basel-City, Schweiz, 4031
- Aktiv, ikke rekrutterende
- University hospital Basel
-
-
-
-
Baden-Wurttemberg
-
Mannheim, Baden-Wurttemberg, Tyskland, 68167
- Aktiv, ikke rekrutterende
- Universitätsklinikum Mannheim, I. Medizinische Klinik
-
-
Bavaria
-
Fürth, Bavaria, Tyskland, 90766
- Aktiv, ikke rekrutterende
- Klinikum Fürth
-
Würzburg, Bavaria, Tyskland, 97080
- Trukket tilbage
- Universitätsklinikum Würzburg
-
-
Schleswig-Holstein
-
Bad Segeberg, Schleswig-Holstein, Tyskland, 23795
- Aktiv, ikke rekrutterende
- Segeberger Kliniken GmbH
-
-
-
-
State of Vienna
-
Vienna, State of Vienna, Østrig, 1090
- Aktiv, ikke rekrutterende
- Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie, Medizinische Universität Wien
-
-
Styria
-
Graz, Styria, Østrig, 8036
- Aktiv, ikke rekrutterende
- Klinische Abteilung für Kardiologie, Medizinische Universität Graz
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Subject is ≥ 18 years of age
-
Subject is able to understand the nature of the study and provide written informed consent.
For sites outside of the United States: Note: For subjects presenting with STEMI and not in a position to read, interpret and sign the informed consent form, oral informed consent is required.
-
Subject is an acceptable candidate for percutaneous coronary intervention (PCI) according to the applicable guidelines.
-
Subject is an acceptable candidate for CABG.
-
Subject is eligible for dual antiplatelet therapy (DAPT) according to guidelines.
-
Subject has clinical evidence of ischemic heart disease, stable or unstable angina pectoris or documented silent ischemia.
-
Subject is willing and able to comply with study follow-up requirements.
Angiographic inclusion criteria:
-
Subject has only one target lesion in a native coronary artery to be treated with the investigational device.
Note: One additional non-target lesion may be treated with a non-investigational treatment (e.g. stent, balloon angioplasty, atherectomy) with the exception of brachytherapy, if it is located in a different coronary artery. The non-target lesion must be treated first and must be deemed an angiographic success. (Angiographic success is defined by a residual diameter stenosis < 30% with TIMI 3 flow, as visually assessed by the physician, without the presence of prolonged chest pain or ECG changes consistent with MI.)
Note: Multiple focal stenoses will be considered as a single lesion if they are amenable to treatment with a single study device.
-
Target lesion must be > 36 mm and ≤ 44 mm in length by operator visual estimate and must be amenable to treatment with a single study device.
-
Target vessel must have a reference vessel diameter of 2.25-4.0 mm by operator visual estimate.
-
For sites in United States: Target lesion must be de novo or restenotic lesion in native coronary artery; restenotic lesion must have been treated with a standard PTCA only.
For sites outside of the United States: Target lesion can be de novo, restenotic or in-stent restenotic, and must be located in a native coronary artery.
-
Target lesion must have angiographic evidence of ≥ 50% and < 100% stenosis (by operator visual estimate which may be assisted by QCA / IVUS / OCT). Target lesion stenosis < 70% should have clinical justification for treatment as per local standards.
-
Target vessel must have a Thrombolysis In Myocardial Infarction (TIMI) flow > 1.
For sites outside of the United States: Note: For STEMI, TIMI flow > 1 prior to stent implantation (after opening the vessel with a guide wire or a balloon).
Exclusion Criteria:
-
For sites in United States only: Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index procedure.
Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment.
-
Subject is hemodynamically unstable.
-
Subject is pregnant and/or breastfeeding or intends to become pregnant during the duration of the study.
-
Subject has a known allergy to contrast medium that cannot be adequately pre-medicated, or any known allergy to thienopyridine, aspirin, both heparin and bivalirudin, L-605 cobalt-chromium (Co-Cr) alloy or one of its major elements (cobalt, chromium, tungsten and nickel), acrylic, fluoropolymers, silicon carbide, PLLA or sirolimus.
-
Revascularization of any target vessel within 12 months prior to the index procedure or previous PCI of any non-target vessel within <72 hours prior to the index procedure.
-
Future planned PCI (including staged procedure) or CABG after the index procedure.
-
Planned surgery or dental surgical procedure within 6 months of index procedure unless dual antiplatelet therapy can be maintained throughout the peri-surgical period.
-
History of a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure.
-
Subjects with active bleeding disorders, active coagulopathy, or any other reason, who are ineligible for DAPT.
-
Subject will refuse blood transfusions.
-
Subject has a left ventricular ejection fraction (LVEF) < 30% within 6 months prior to or during the index procedure that was documented by any method.
-
Subject is dialysis dependent or has impaired renal function (i.e., serum creatinine > 2.5 mg/dL or 221 µmol/L, determined within 7 days prior to the index procedure).
-
Subject has a documented white blood cell count < 3,000 white blood cells/mm3 or a documented platelet count < 100,000 platelets/mm3 or > 700,000 platelets/mm3.
-
Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted).
-
Subject is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure or has a malignancy that is not in remission.
-
Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e. triple therapy) can be maintained according to guidelines.
-
Subject has life expectancy of < 1 year.
-
Subject is currently participating or plans to participate in another clinical investigation with an investigational device or an investigational drug.
-
In the investigator's opinion, subject will not be able to comply with the follow-up requirements.
Angiographic exclusion criteria:
-
Target lesion is excluded if it meets any of the following criteria:
- Lesion is located within or treated through a saphenous vein graft or arterial graft.
- Lesion location is within the left main coronary artery.
- Lesion location is within 3 mm of the origin of the left anterior descending (LAD) or left circumflex (LCX) coronary arteries.
- Involves a side branch of > 2.0 mm in diameter that requires a two-device strategy after pre-dilatation.
- Lesion is totally occluded (100% stenosis).
- For sites in United States only: Lesion is a restenotic lesion that was previously treated with a bare metal or drug eluting stent (in-stent restenosis).
-
Target vessel/lesion is excessively tortuous/angulated or is severely calcified, that would prevent complete inflation of an angioplasty balloon. This assessment should be based on visual estimation.
-
Site sites in the United States: Target vessel has angiographic evidence of thrombus.
For sites outside of the United States: Target vessel has angiographic evidence of unresolved large thrombus burden despite of thrombus aspiration.
Note: Thrombus aspiration is left at the discretion of the implanting physician.
-
Target vessel was treated with brachytherapy any time prior to the index procedure.
-
Unsuccessful target lesion pre-dilatation, defined as residual stenosis > 50% (by visual estimation) and/or angiographic complications (e.g., distal embolization, side branch closure, dissection greater than National Heart, Lung, Blood Institute type C), and/or, for sites outside of the United States, coronary aneurysms.
-
Non-target lesion is excluded if it meets any of the following criteria:
- Any of the target lesion angiographic exclusion criteria except for 1c
- Lesion is located within the target vessel.
- Lesion is > 36 mm by operator visual estimate.
- Lesion requires additional, unplanned stents to treat a complication.
- Lesion treatment is not deemed an angiographic success. (Angiographic success is defined by a residual diameter stenosis < 30% with TIMI 3 flow, as visually assessed by the physician, without the presence of prolonged chest pain or ECG changes consistent with MI.)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Orsiro Mission 48 mm Sirolimus-eluerende koronarstentsystem
|
Orsiro Mission is composed of a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Target Lesion Failure (TLF) rate at 12 months post-index procedure
Tidsramme: 12 months
|
The primary endpoint will be target lesion failure (TLF) rate at 12 months post-index procedure. TLF is defined as a composite of cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (TV-MI), or clinically driven target lesion revascularization (CD-TLR). |
12 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Død af alle årsager
Tidsramme: 1, 6, 12 måneder og 2, 3 og 5 år efter indeksprocedure
|
1, 6, 12 måneder og 2, 3 og 5 år efter indeksprocedure
|
|
|
Ethvert myokardieinfarkt (MI)
Tidsramme: 1, 6, 12 måneder og 2, 3 og 5 år efter indeksprocedure
|
1, 6, 12 måneder og 2, 3 og 5 år efter indeksprocedure
|
|
|
Hjertedød eller myokardieinfarkt (MI)
Tidsramme: 1, 6, 12 måneder og 2, 3 og 5 år efter indeksprocedure
|
1, 6, 12 måneder og 2, 3 og 5 år efter indeksprocedure
|
|
|
Target læsion revaskularization (TLR)
Tidsramme: 1, 6, 12 måneder og 2, 3 og 5 år efter indeksprocedure
|
1, 6, 12 måneder og 2, 3 og 5 år efter indeksprocedure
|
|
|
Målkarrevaskularisering (TVR)
Tidsramme: 1, 6, 12 måneder og 2, 3 og 5 år efter indeksprocedure
|
1, 6, 12 måneder og 2, 3 og 5 år efter indeksprocedure
|
|
|
Device success
Tidsramme: Hospital Discharge (6-24 hours post-index procedure)
|
Device success, defined as attainment of < 30% residual stenosis of the target lesion (based on operator visual estimate) using the Orsiro Mission study stent only. |
Hospital Discharge (6-24 hours post-index procedure)
|
|
Procedure success
Tidsramme: Hospital Discharge (6-24 hours post-index procedure)
|
Procedure success, defined as attainment of < 30% residual stenosis of the target lesion (based on operator visual estimate) using the Orsiro Mission study stent only without occurrence of in-hospital major adverse cardiac events (MACE). |
Hospital Discharge (6-24 hours post-index procedure)
|
|
Major cardiac adverse events (MACE) and individual MACE components
Tidsramme: 1, 6, 12 months and 2, 3, and 5 years post-index procedure
|
MACE is defined as a composite of all-cause death, Q-wave or non-Q-wave MI, and any clinically driven target lesion revascularization (TLR). |
1, 6, 12 months and 2, 3, and 5 years post-index procedure
|
|
Target lesion failure (TLF) and individual TLF components
Tidsramme: 1, 6, 12 months and 2, 3, and 5 years post-index procedure
|
TLF is defined as a composite of cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (TV-MI), or clinically driven target lesion revascularization (CD-TLR). |
1, 6, 12 months and 2, 3, and 5 years post-index procedure
|
|
Target vessel failure (TVF) and individual TVF components
Tidsramme: 1, 6, 12 months and 2, 3, and 5 years post-index procedure
|
TVF is defined as a composite of cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (TV-MI), and clinically driven target vessel revascularization (CD-TVR). |
1, 6, 12 months and 2, 3, and 5 years post-index procedure
|
|
Stent thrombosis
Tidsramme: 1, 6, 12 months and 2, 3, and 5 years post-index procedure
|
Stent thrombosis will be assessed according to Academic Research Consortium - 2 (ARC-2) definitions. |
1, 6, 12 months and 2, 3, and 5 years post-index procedure
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- G240288
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
No IPD sharing is planned at this time. This study evaluates an investigational device under an FDA IDE. The sponsor may consider sharing de-identified IPD under controlled access following completion of primary endpoint analysis and regulatory review. Summary results will be reported in scientific publications and public registries.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .